Article

Heparin May Reduce SARS-CoV-2 Infection Risk

New research shows the anticoagulant binds tightly with the coronavirus’ surface spike protein.

An original version of this article was published on sister publication Contagion.

US Food and Drug Administration (FDA)-approved anticoagulant heparin may lower the odds of SARS-CoV-2 infection, according to investigators from the Rensselaer Polytechnic Institute (RPI).

SARS-CoV-2 uses its surface spike protein to bind to human cells. Heparin, a blood thinner also available in non-anticoagulant formulations, binds tightly with the coronavirus’ surface spike protein. A team led by Robert Linhardt, PhD, professor of chemistry and chemical biology at RPI, predicted that this tight binding might interfere with SARS-CoV-2 infection.

SARS-CoV-2 is particularly difficult for health systems to respond to; the virus presents a perfect storm of largely mild and asymptomatic transmission dynamics combined with the danger for very severe infection in a sizable minority of at-risk individuals.

Efforts to adapt to the unique virologic profile of SARS-CoV-2 have been greatly frustrated by the paucity of effective treatment and prevention options. In order to improve clinical outcomes, a variety of investigational therapies are being studied for use among patients with COVID-19. Specialty medications like remdesivir, favipiravir, and hydroxychloroquine have emerged from relative obscurity to garner intense media interest.

The investigators speculated that heparin could be introduced into the body using a nasal spray or nebulizer in order to run interference on the coronavirus’ binding processes, lowering the odds of infection. “Decoy” strategies have been previously used against Zika virus, influenza A, and dengue.

"This approach could be used as an early intervention to reduce the infection among people who have tested positive, but aren't yet suffering symptoms. But we also see this as part of a larger antiviral strategy," Linhardt said. "Ultimately, we want a vaccine, but there are many ways to combat a virus, and as we've seen with HIV, with the right combination of therapies, we can control the disease until a vaccine is found."

Using a surface plasmon resonance direct binding assay, the study team discovered that SARS-CoV-2’s spike protein binds more tightly to immobilized heparin (KD = 40 pM VS 73 pM) than that of SARS-CoV and MERS-CoV (500 nM and 1 nM).

While the use of heparin as a COVID-19 treatment is currently theoretical, the study also serves a catalyst to further investigate the role of glycosaminoglycans in SARS-CoV-2 pathogenesis. Furthermore, the authors expressed hope that their findings provide a basis for further study of heparin-based interventions for COVID-19 patients exhibiting thrombotic complications.

"As soon as our labs reopen we are planning to begin animal studies on heparin administered to the nose and lung," Linhardt said.

The analysis was published online in Antiviral Research on Wednesday.

Related Videos
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.